WallabyPhenox logo — Leading Innovator in Interventional Neuroradiology

WallabyPhenox

Leading Innovator in Interventional Neuroradiology

Founded 2005 Germany Bochum, Germany 225 employees Acquired Total: $990.00K Biotechnology, Medical Devices

General Information

Company Name WallabyPhenox
Founded Year 2005
Location Germany Bochum, Germany
Employees 225
Industries Biotechnology, Medical Devices
Funding Stage Acquired
Business Model B2B, B2B2C
Revenue Model Product Sales, One Time Purchase, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with WallabyPhenox. To contact WallabyPhenox, visit phenox.net.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does WallabyPhenox compare?

A PDF of WallabyPhenox and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting WallabyPhenox soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About WallabyPhenox

WallabyPhenox, a rebranded entity following its 2022 acquisition by Wallaby Medical, is a leading innovator in the realm of interventional neuroradiology. Originally established in 2005 under the name phenox GmbH, the company has consistently pursued the development of groundbreaking technologies for neurovascular disease treatment.

Their premier product lineup includes the Mechanical Thrombectomy System pRESET, along with the p64, p48 MW, and p64 MW Flow Diverters designed for complex intracranial aneurysms. Another standout, the pCONUS Implant, addresses wide-neck bifurcation aneurysms. A highlight is their HPC Technology, which dramatically enhances patient safety by minimizing implant thrombogenicity.

Operating from their headquarters in Germany, the company’s integrative approach to neurovascular solutions is underscored by its exclusive distribution of the Avenir Coiling System. Their last major financial activity was their acquisition by Wallaby Medical on 01 April 2022.

Business keywords: Interventional Neuroradiology, Neurovascular Devices, Ischemic Stroke Treatment, Hemorrhagic Stroke Treatment, Mechanical Thrombectomy Systems, Flow Diverters, Aneurysm Treatment Devices, Hydrophilic Polymer Coating, Bifurcation Aneurysm Implants, Neurovascular Retrievers, Flow Modulation Devices, Balloon Catheters, Microguidewires, Innovative Medical Technology, Neurovascular Implants

Services & Products

Aneurysm Treatment
Ischemic Stroke Treatment
Medical Device Access and Delivery
Innovative Coating Technologies

Target Customers

Healthcare Professionals Doctors Physicians Patients Non-Medical Personnel

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition Undisclosed 1
Wallaby Medical
01 Apr 2022
Grant €990.00K -
01 May 2021
Early VC Undisclosed -
01 Aug 2010

WallabyPhenox Alternatives & Competitors

View All Alternatives
WallabyPhenox vs
Perfuze
Perfuze Ireland

Neurovascular medical device company developing technology for Ischemic Stroke

Series A
33 employees
Biotechnology, Health Care
WallabyPhenox vs
DIAFIR
DIAFIR France

DIAFIR developps, manufactures and markets in situ and fast biological analytical tools based upon u...

Venture round
2 employees
Biotechnology, Manufacturing
WallabyPhenox vs
Mainstay Medical
Mainstay Medical United States

First and Only FDA Approved Restorative Therapy for Chronic Mechanical Low Back Pain

IPO
183 employees
Biotechnology, Health Care

FAQ About WallabyPhenox

Leading Innovator in Interventional Neuroradiology
WallabyPhenox was founded in 2005.
WallabyPhenox is headquartered in Bochum, Germany.
WallabyPhenox operates in Biotechnology and Medical Devices. Its work centres on Interventional Neuroradiology, Neurovascular Devices, Ischemic Stroke Treatment and Hemorrhagic Stroke Treatment. Its customers include Healthcare Professionals, Doctors and Physicians.
WallabyPhenox has a B2B and B2B2C business model. Its revenue comes from Product Sales, One Time Purchase and Service Fee.
WallabyPhenox has approximately 225 employees.
WallabyPhenox has completed 3 funding rounds, raising a total of $990.00K. The latest funding stage is Acquired.
WallabyPhenox offers: Aneurysm Treatment, Ischemic Stroke Treatment, Medical Device Access and Delivery, Innovative Coating Technologies.
Top alternatives and competitors to WallabyPhenox include Perfuze, DIAFIR, Mainstay Medical, Bioxis Pharmaceuticals, SyMap Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
WallabyPhenox and Perfuze are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for WallabyPhenox, https://bouncewatch.com/company/wallabyphenox, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes